menu search

3 gene editing stocks to buy now or you'll be kicking yourself later

To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure g...

January 25, 2023, 5:20 pm

Adaptive biotechnologies to report fourth quarter and full year 2022 financial results on february 14, 2023

SEATTLE, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage bi...

January 23, 2023, 4:05 pm

Bionano genomics announces the final speaker lineup for symposium 2023 with 30 ogm presentations and live panel discussions across a wide range of genetic disease and cancer research applications

27 different customers representing North America and Europe 30 oral presentations across four consecutive days 34 scientific posters will be featured...

January 20, 2023, 1:00 pm

Diving into dyne therapeutics

Shares of genetic muscle disease concern Dyne Therapeutics, Inc. have enjoyed a recent bounce on the ba...

January 19, 2023, 5:01 pm

3 crispr stocks that will make you filthy rich in 10 years

CRISPR could revolutionize the way we treat thousands of diseases.  Many of these diseases occur when mutations affect genes, or when people have the...

January 18, 2023, 3:40 pm

Fulcrum therapeutics announces pricing of upsized public offering of common stock

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused ...

January 18, 2023, 4:15 am

Omega therapeutics to present trial-in-progress poster for phase 1/2 mychelangelo™ i study at the american society of clinical oncology gastrointestinal cancers symposium

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pion...

January 17, 2023, 7:00 am

Fulgent alert: bragar eagel & squire, p.c. is investigating fulgent genetics, inc. on behalf of long-term stockholders and encourages investors to contact the firm

NEW YORK, Jan. 13, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potent...

January 14, 2023, 2:00 am

Volitionrx announces expansion of availability of nu.q vet cancer test availability through idexx's reference laboratory network

VolitionRx Ltd (NYSE-A:VNRX) has announced the availability of its Nu.Q Vet Cancer Test through the IDEXX Laboratories Inc reference laboratory netwo...

January 12, 2023, 9:23 am

Why prenetics global stock is skyrocketing today

The company announced a key FDA clearance....

January 10, 2023, 11:32 am

Solid biosciences reports inducement grant to chief financial officer and treasurer

CHARLESTOWN, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing g...

January 9, 2023, 9:26 pm

Solid biosciences to present at the 41st annual j.p. morgan healthcare conference

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing g...

January 9, 2023, 8:00 am

Volitionrx highlights 2022 achievements as it advances to commercial operations

VolitionRx (NYSE-A:VNRX) has outlined its key achievements in 2022 as the organization transitions from a company solely focused on research and devel...

January 9, 2023, 6:46 am

Celularity’s placental-derived allogeneic cell therapy provides clinically meaningful benefit and durable biological effect in patients with moderate to severe crohn’s disease in phase 1, phase 1b/2a

Legacy studies employing a single treatment course of two infusions seven days apart demonstrated greatest benefit in three early studies Data support...

January 6, 2023, 1:10 pm

Crispr, genetics and ai — why 2023 could be the year for biotech stocks

If there's one biotech area to watch in 2023, it's genetic medicine, like CRISPR. But other trends also...

January 6, 2023, 8:00 am

Xrlv: low-volatility portfolio comes with superior quality, disenchanting valuation

XRLV offers exposure to bellwether U.S. equities that are capable of benefiting from rising interest rates and are not prone to fr...

January 4, 2023, 8:23 pm

Sophia genetics to present at the j.p. morgan 2023 healthcare conference

BOSTON & LAUSANNE, Switzerland--( BUSINESS WIRE )--SOPHiA GenetiCS SA (NASDAQ: SOPH) today announced th...

January 4, 2023, 4:02 pm

Ultragenyx to present at the 41st annual j.p. morgan healthcare conference

NOVATO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the developmen...

January 4, 2023, 6:00 am

eneti: still cheap, although the low-hanging fruit is gone

eneti has posted decent performance over the past year, but it continues to trade at a cheap valuation ...

January 3, 2023, 4:08 am

Opus genetics announces acquisition of the rights to two gene therapy product candidates for inherited retinal diseases

Opus to advance preclinical development programs for BEST1– and RHO-related retinal diseases Deal expands Opus’ addressable patient population for...

December 28, 2022, 1:00 pm


Search within

Pages Search Results: